

NYU9301M.PR3
CSE30
DEB/CSE/jwb
12/05/95

181

PATENT APPLICATION
Docket No.: NYU93-01M

Duplicate
by 17/1C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Junming Le, Jan Vileck, Peter Daddona, John
Ghrayeb, David Knight and Scott Siegel E40

Serial No.: 08/192,102 4100 Group: 1806

Filed: February 4, 1994 Examiner: M. Nisbet

For: ANTI-TNF ANTIBODIES AND PEPTIDES OF HUMAN
TUMOR NECROSIS FACTOR

CERTIFICATE OF FACSIMILE TRANSMISSION	
I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office:	
on	12/5/95
Date	Judy Breen
Signature	
Judy Breen	
Typed or printed name of person signing certificate	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Please amend the claims as follows:

Cancel Claims 71-90 and add new Claims 91-97 therefor.

91. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody

- 2 -

comprises a non-human variable region or a TNF-binding portion thereof and a human constant region.

92. The method of Claim 91 wherein the non-human variable region is of murine origin.
93. The method of Claim 91 wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to a monoclonal antibody selected from the group consisting of A2 or cA2.
94. The method of Claim 91 wherein said anti-TNF chimeric antibody does not bind to one or more epitopes included in amino acids 11-13, 37-42, 4957 or 155-157 of SEQ ID NO.: 1 of hTNF.
95. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to a monoclonal antibody selected from the group consisting of A2 or cA2.
96. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody binds to amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF.

-3-

97. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of chimeric anti-TNF antibody cA2.

Claims 91-97 are pending. Entry of the Preliminary Amendment prior to examination of the application is respectfully requested and pursuant to the telephone conversation between Examiner Nisbet and the undersigned on December 1, 1995. This amendment is made to reduce issues on examination expedite prosecution. Clearly, no new matter is presented by this amendment. The application is now in condition for allowance. If the Examiner feels that a telephonic interview would facilitate examination, he is encouraged to telephone the undersigned at (617) 861-6240.

Respectfully submitted,



Carolyn S. Elmore

Registration No. 37,567

Patent Agent

(617) 861-6240

Lexington, MA 02173

Dated: 12/5/95